Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
lirafugratinib (RLY-4008)
i
Other names:
RLY-4008
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Relay Therap
Drug class:
FGFR2 inhibitor
Related drugs:
‹
erdafitinib (70)
Max-40279 (2)
HMPL-453 (1)
TT-00434 (1)
ABSK061 (0)
ASP5878 (0)
CGT4859 (0)
DS-1123 (0)
HH185 (0)
LY2874455 (0)
S-49076 (0)
RPT835 (0)
PBI-05204 (0)
erdafitinib (70)
Max-40279 (2)
HMPL-453 (1)
TT-00434 (1)
ABSK061 (0)
ASP5878 (0)
CGT4859 (0)
DS-1123 (0)
HH185 (0)
LY2874455 (0)
S-49076 (0)
RPT835 (0)
PBI-05204 (0)
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
RLY-4008
Sensitive: C2 – Inclusion Criteria
RLY-4008
Sensitive
:
C2
RLY-4008
Sensitive: C2 – Inclusion Criteria
RLY-4008
Sensitive
:
C2
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
RLY-4008
Sensitive: C3 – Early Trials
RLY-4008
Sensitive
:
C3
RLY-4008
Sensitive: C3 – Early Trials
RLY-4008
Sensitive
:
C3
FGFR2 N549K
Endometrial Cancer
FGFR2 N549K
Endometrial Cancer
RLY-4008
Sensitive: D – Preclinical
RLY-4008
Sensitive
:
D
RLY-4008
Sensitive: D – Preclinical
RLY-4008
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login